GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0072594110 | Esophagus | ESCC | establishment of protein localization to organelle | 311/8552 | 422/18723 | 3.02e-32 | 2.13e-29 | 311 |
GO:0006605111 | Esophagus | ESCC | protein targeting | 229/8552 | 314/18723 | 4.93e-23 | 1.01e-20 | 229 |
GO:0006839110 | Esophagus | ESCC | mitochondrial transport | 187/8552 | 254/18723 | 8.35e-20 | 9.81e-18 | 187 |
GO:0072655110 | Esophagus | ESCC | establishment of protein localization to mitochondrion | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
GO:0070585110 | Esophagus | ESCC | protein localization to mitochondrion | 100/8552 | 125/18723 | 2.96e-15 | 1.77e-13 | 100 |
GO:0006626110 | Esophagus | ESCC | protein targeting to mitochondrion | 81/8552 | 100/18723 | 3.60e-13 | 1.67e-11 | 81 |
GO:005160418 | Esophagus | ESCC | protein maturation | 189/8552 | 294/18723 | 7.64e-11 | 2.39e-09 | 189 |
GO:001648514 | Esophagus | ESCC | protein processing | 134/8552 | 225/18723 | 1.81e-05 | 1.60e-04 | 134 |
GO:007259416 | Prostate | BPH | establishment of protein localization to organelle | 142/3107 | 422/18723 | 4.01e-18 | 1.31e-15 | 142 |
GO:000660518 | Prostate | BPH | protein targeting | 102/3107 | 314/18723 | 2.51e-12 | 2.05e-10 | 102 |
GO:000683916 | Prostate | BPH | mitochondrial transport | 79/3107 | 254/18723 | 6.77e-09 | 2.38e-07 | 79 |
GO:007265516 | Prostate | BPH | establishment of protein localization to mitochondrion | 42/3107 | 120/18723 | 7.32e-07 | 1.39e-05 | 42 |
GO:007058516 | Prostate | BPH | protein localization to mitochondrion | 43/3107 | 125/18723 | 9.29e-07 | 1.70e-05 | 43 |
GO:00516049 | Prostate | BPH | protein maturation | 80/3107 | 294/18723 | 2.64e-06 | 4.23e-05 | 80 |
GO:000662616 | Prostate | BPH | protein targeting to mitochondrion | 34/3107 | 100/18723 | 1.64e-05 | 2.05e-04 | 34 |
GO:00164855 | Prostate | BPH | protein processing | 62/3107 | 225/18723 | 2.22e-05 | 2.67e-04 | 62 |
GO:007259417 | Prostate | Tumor | establishment of protein localization to organelle | 151/3246 | 422/18723 | 3.19e-20 | 2.83e-17 | 151 |
GO:000660519 | Prostate | Tumor | protein targeting | 109/3246 | 314/18723 | 6.11e-14 | 7.30e-12 | 109 |
GO:000683917 | Prostate | Tumor | mitochondrial transport | 84/3246 | 254/18723 | 7.17e-10 | 3.57e-08 | 84 |
GO:007058517 | Prostate | Tumor | protein localization to mitochondrion | 47/3246 | 125/18723 | 5.20e-08 | 1.58e-06 | 47 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MIPEP | SNV | Missense_Mutation | novel | c.1063N>T | p.Pro355Ser | p.P355S | Q99797 | protein_coding | deleterious(0.03) | possibly_damaging(0.733) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MIPEP | SNV | Missense_Mutation | novel | c.936A>C | p.Lys312Asn | p.K312N | Q99797 | protein_coding | tolerated(0.05) | benign(0.091) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
MIPEP | SNV | Missense_Mutation | novel | c.521N>T | p.Ser174Phe | p.S174F | Q99797 | protein_coding | deleterious(0.04) | benign(0.013) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
MIPEP | SNV | Missense_Mutation | novel | c.2032C>A | p.Leu678Ile | p.L678I | Q99797 | protein_coding | tolerated(0.21) | possibly_damaging(0.574) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MIPEP | SNV | Missense_Mutation | rs141693205 | c.1924G>A | p.Ala642Thr | p.A642T | Q99797 | protein_coding | deleterious(0) | possibly_damaging(0.84) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
MIPEP | SNV | Missense_Mutation | rs761087143 | c.715N>T | p.Arg239Cys | p.R239C | Q99797 | protein_coding | deleterious(0.03) | possibly_damaging(0.582) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
MIPEP | SNV | Missense_Mutation | novel | c.940N>A | p.Pro314Thr | p.P314T | Q99797 | protein_coding | deleterious(0.01) | benign(0.424) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MIPEP | SNV | Missense_Mutation | | c.787N>A | p.Val263Met | p.V263M | Q99797 | protein_coding | tolerated(0.07) | benign(0.378) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MIPEP | SNV | Missense_Mutation | | c.811T>G | p.Phe271Val | p.F271V | Q99797 | protein_coding | deleterious(0) | possibly_damaging(0.899) | TCGA-BS-A0TC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MIPEP | SNV | Missense_Mutation | | c.1297N>G | p.Ile433Val | p.I433V | Q99797 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-D1-A163-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD |